Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

20. december 2019 opdateret af: Biogen

A Phase I, Randomized, Subject and Investigator-Blind, Sponsor Open, Multiple Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

The primary objective of this study evaluates the safety and tolerability of multiple, escalating doses of PF-04958242 administered orally to healthy adult participants.This study also evaluates the plasma and urine multiple dose pharmacokinetics (PK) of PF-04958242.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

A decision was made to terminate the B1701002 study so that emerging data from the study and from a preclinical study in rats could be further examined and incorporated into a new study design and protocol.

This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

20

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Singapore
      • Singapore, Singapore, 188770
        • Research Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 55 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • Body Mass Index (BMI) of 17.5 to 30.5 kilograms per meter quared (kg/m2);
  • Total body weight >50 kilograms (kg) (110 pounds [lbs]);

Key Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing);
  • Positive urine drug screen;
  • Pregnant or nursing females, and females of child bearing potential;
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Cohort 1
Participants received an oral solution of 0.03 milligrams (mg) of PF-04958242, every 12 hours for 14 days.
Medicin: PF-04958242
Indgives som specificeret i behandlingsarmen
Eksperimentel: Cohort 2
Participants received an oral solution of 0.05 mg of PF-04958242, every 24 hours for 14 days.
Medicin: PF-04958242
Indgives som specificeret i behandlingsarmen
Eksperimentel: Cohort 3
Participants received an oral solution of 0.10 mg of PF-04958242, every 24 hours for 14 days.
Medicin: PF-04958242
Indgives som specificeret i behandlingsarmen
Eksperimentel: Cohort 4
Participants received an oral solution of 0.15 mg of PF-04958242, every 24 hours for 14 days.
Medicin: PF-04958242
Indgives som specificeret i behandlingsarmen
Eksperimentel: Cohort 5
Participants received an oral solution of 0.20 mg of PF-04958242, every 24 hours for 14 days.
Medicin: PF-04958242
Indgives som specificeret i behandlingsarmen
Eksperimentel: Cohort 6
Participants received an oral solution of 0.25 mg of PF-04958242, every 24 hours for 14 days.
Medicin: PF-04958242
Indgives som specificeret i behandlingsarmen
Placebo komparator: Matching Placebo
Participants received an oral solution of matching placebo, every 12 or 24 hours for 14 days.
Medicin: Placebo
Indgives som specificeret i behandlingsarmen

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants Experiencing Adverse Events and Serious Adverse Events
Tidsramme: Baseline up to Day 23
An adverse event is any untoward medical occurrence in a clinical investigation subject administered a product or medical device. A serious adverse event or serious adverse drug reaction is any untoward medical occurrence at any dose that: Results in death; Is life-threatening (immediate risk of death); Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity; Results in congenital anomaly/birth defect.
Baseline up to Day 23
Maximum Plasma Drug Concentration (Cmax) for Single Dose
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Time to Reach Maximum Plasma Concentration (Tmax) for Single Dose
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Area Under the Concentration Time-curve During a Dosage Interval (AUCτ) for Single Dose
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Maximum Observed Plasma Concentration (Cmax) for Steady State
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Area Under the Plasma Drug Concentration-Time Curve During a Dosage Interval (AUCτ) for Steady State
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Apparent Total Clearance of the Drug from Plasma (CL/F) for Steady State
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Apparent Volume of Distribution During Terminal Phase (Vz/F) for Steady State
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Elimination Half-Life (t1/2) for Steady State
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Accumulation Ratio (AUC(τ,ss)/AUC(τ,sd)) for Steady State
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17
Percent of Dose Eliminated in Urine Unchanged (Ae%)
Tidsramme: Day 14
Day 14
Amount of PF-04958242 Eliminated in Urine Unchanged (Ae)
Tidsramme: Day 14
Day 14
Renal Clearance (CLr)
Tidsramme: Day 14
Day 14
Time to Reach Maximum Plasma Concentration (Tmax) for Steady State
Tidsramme: Day 1 and at multiple time points up to Day 17
Day 1 and at multiple time points up to Day 17

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Biogen

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

24. november 2010

Primær færdiggørelse (Faktiske)

3. maj 2011

Studieafslutning (Faktiske)

3. maj 2011

Datoer for studieregistrering

Først indsendt

2. november 2010

Først indsendt, der opfyldte QC-kriterier

9. november 2010

Først opslået (Skøn)

10. november 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. december 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. december 2019

Sidst verificeret

1. december 2019

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • B1701002

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med PF-04958242

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Kyrgyzstan

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner